

Project Title	Funding	Strategic Plan Objective	Institution
1/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$1	Q4.L.C	Indiana University-Purdue University Indianapolis
2/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$171,791	Q4.L.C	Seattle Children's Hospital
3/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$200,372	Q4.L.C	University of California, Los Angeles
4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$168,533	Q4.L.C	Yale University
Acamprosate in Youth with Autism Spectrum Disorders	\$149,719	Q4.S.F	Cincinnati Childrens Hospital Medical Center
ACE Center: Augmenting language interventions for ASD: A translational approach	\$269,087	Q4.L.A	University of California, Los Angeles
ACE Network: Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)	\$2,435,695	Q4.L.A	University of North Carolina at Chapel Hill
A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism	\$0	Q4.L.A	Holland Bloorview Kids Rehabilitation Hospital
A randomized, controlled trial of intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder	\$0	Q4.S.C	Massachusetts General Hospital
Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$0	Q4.L.A	Stanford University
Controlled trial of sertraline in young children with Fragile X Syndrome	\$285,943	Q4.L.A	University of California, Davis
Evaluation of a melanocortin agonist to improve social cognition in autism	\$74,675	Q4.L.A	University of Sydney
Exploration of resting-state network dynamics in autism spectrum disorders	\$30,000	Q4.Other	Harvard University
Fast-as -new experimental medicine studies: Fast-fail trials in autism spectrum	\$2,312,083	Q4.Other	University of California, Los Angeles
Human Clinical Trial of IGF-1 in Children with Idiopathic ASD	\$25,000	Q4.L.C	Icahn School of Medicine at Mount Sinai
Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)	\$0	Q4.S.C	Holland Bloorview Kids Rehabilitation Hospital
Metabolic factors affecting gamma synchrony	\$0	Q4.S.C	University of Louisville; Northeastern University
Metabolic signature of antipsychotics used in the treatment of autism	\$0	Q4.L.C	University of Cincinnati
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders	\$99,971	Q4.L.C	Indiana University
Neuroactive steroid GABAA receptor positive modulators for fragile X syndrome	\$162,500	Q4.Other	Sage Therapeutics, Inc.
Randomized controlled trial of oxytocin treatment for social deficits in children with autism	\$53,600	Q4.L.A	Stanford University
Randomized phase 2 trial of RAD001 (an MTOR inhibitor) in patients with tuberous sclerosis complex	\$0	Q4.L.A	Boston Children's Hospital

Project Title	Funding	Strategic Plan Objective	Institution
The effects of intranasal oxytocin on social cognition and neural activity	\$421,790	Q4.S.A	Emory University
The role of vasopressin in the social deficits of autism	\$235,500	Q4.L.A	Stanford University
The use of non-invasive brain stimulation to improve social relating in autism spectrum disorders	\$28,000	Q4.S.F	Monash University
Treating autism and epileptic discharges with valproic acid	\$68,088	Q4.S.A	Boston Children's Hospital
Treatment of Overweight Induced by Antipsychotic Medication in Young People with ASD	\$468,376	Q4.L.A	Holland Bloorview Rehabilitation Hospital

